Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RGNX Catalyst Timeline
Dated clinical, regulatory and corporate events for REGENXBIO Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for REGENXBIO Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How RGNX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | NAVSUNLI (clemidsogene lanparvovec-sngl, RGX-121) | BLA Submission | BLA |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RGX-202 Gene TherapiesNCT05693142 | Duchenne Muscular Dystrophy | Phase 2/3 | ACTIVE NOT_RECRUITING | 65 | Jun 1, 2028 | ||||||
| RGX-121 Gene TherapiesNCT03566043 | Mucopolysaccharidosis Type II (MPS II) | Phase 2/3 | ACTIVE NOT_RECRUITING | 54 | Aug 1, 2025 | ||||||
| RGX-121 Gene TherapiesNCT07236606 | MPS II | NDA/BLA | ACTIVE NOT_RECRUITING | 2 | May 30, 2031 | ||||||
| RGX-314 Gene TherapiesCompletedNCT03066258 | Neovascular Age-related Macular Degeneration | Phase 1/2 | COMPLETED | 42 | Jun 17, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every RGNX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| surabgene lomparvovec | wet AMD and diabetic retinopathy | Phase 1/2a | 2026-07-18 | Stable to improved vision through 5 years in wet AMD patients; No drug-related intraocular inflammation observed; >2-step DRSS improvement in majority of NPDR participants at 2.5 yearsRead More | REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ciongoli Gregory AustinDirector | Buy | 53,407 118,035 held | $9.36 | 08/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RGNX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 2.8 % (-20 %) | 38.02 M | 5.05 M | 15.56% ( 679.70 K) |
Ownership Trends
RGNX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How RGNX ranks across every disease it competes in
RGNX News
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
REGENXBIO reported its Q3 2026 financial results, highlighting progress in its gene therapy pipeline. The company is on track to submit a BLA for RGX-202 in Q1 2027 and expects pivotal data for sura-vec in Q4 2026. Despite a clinical hold on RGX-121, REGENXBIO maintains a strong cash position of $251 million.
Read more →REGENXBIO to Participate in Stifel 2026 Healthcare Conference
REGENXBIO Inc. will participate in the Stifel 2026 Healthcare Conference on November 11, 2026. The event will feature a fireside chat at 9:20 a.m. ET in New York. A live webcast will be available on the company's website, with an archived replay for 30 days.
Read more →REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. will hold a conference call on November 5 to discuss its third quarter financial results and operational highlights. The call is scheduled for 8:00 a.m. ET, and listeners can register online. The company is known for its advancements in gene therapy, particularly in treating rare and retinal diseases.
Read more →REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
REGENXBIO Inc. will host an investor event on October 20, 2026, to discuss the clinical program for surabgene lomparvovec (sura-vec) in wet AMD. The event will feature insights from leading retina specialists and is set to precede the anticipated topline pivotal data readout in Q4 2026. The event will be held in New York and available via webcast.
Read more →REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
REGENXBIO presented positive three-year data for surabgene lomparvovec at the Retina Society Annual Scientific Meeting. The Phase II ALTITUDE study showed that 60% of participants with non-proliferative diabetic retinopathy achieved significant improvement without additional treatment. No safety concerns were reported, reinforcing the therapy's potential as a transformative one-time treatment.
Read more →REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. will participate in two upcoming investor conferences in New York on September 15 and 16, 2026. The company aims to showcase its advancements in gene therapy, particularly its late-stage pipeline targeting rare and retinal diseases. Live webcasts of the events will be available on their website.
Read more →REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
REGENXBIO Inc. has appointed Greg Ciongoli to its Board of Directors as the company prepares for its next phase of growth. Ciongoli brings extensive experience in biotechnology investing and corporate strategy. Concurrently, long-serving board members Jerry Karabelas and Jean Bennett are retiring. The company aims to leverage Ciongoli's expertise to advance its late-stage gene therapy pipeline.
Read more →REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
REGENXBIO has announced a clinical hold on its gene therapy RGX-121 for MPS II after asymptomatic spine MRI findings were reported in five study participants. The company does not anticipate resubmitting the Biologics License Application soon. Despite the hold, participants remain clinically stable, and REGENXBIO is focusing on other therapies in its pipeline.
Read more →REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO reported strong financial results and operational highlights for Q2 2026, with a focus on advancing its gene therapy pipeline. Key developments include the initiation of the RGX-202 BLA submission for Duchenne muscular dystrophy and positive data from ongoing trials for RGX-121 and surabgene lomparvovec. The company raised over $200 million to support its operations and extend its cash runway into Q4 2027.
Read more →REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. will host a conference call on August 6, 2026, at 8:00 a.m. ET to discuss its second quarter financial results and operational highlights. The call will include a question and answer session for analysts. A replay will be available shortly after the call concludes.
Read more →REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO presented positive long-term data for surabgene lomparvovec (sura-vec) at the ASRS Annual Meeting. The gene therapy demonstrated stable to improved vision in wet AMD patients over five years, with no drug-related intraocular inflammation. Additionally, it showed significant improvements in diabetic retinopathy patients at 2.5 years. Topline data from pivotal studies are expected in Q4 2026.
Read more →REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
REGENXBIO Inc. has announced the pricing of a public offering of over 10 million shares of common stock at $9.00 each, along with pre-funded warrants. The offering is expected to raise around $100 million and is set to close on July 20, 2026. The company has granted underwriters a 30-day option to purchase additional shares.
Read more →REGENXBIO Announces Proposed Public Offering of Common Stock
REGENXBIO Inc. has announced a proposed public offering of $100 million in common stock, subject to market conditions. The company plans to grant underwriters a 30-day option to purchase additional shares. This offering is part of their strategy to support their gene therapy pipeline, which includes treatments for various diseases.
Read more →REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
REGENXBIO has announced the dosing of the first patient in its Phase IIb/III NAAVIGATE trial for surabgene lomparvovec, a gene therapy for diabetic retinopathy. The company will receive a $100 million milestone payment from AbbVie. This trial aims to evaluate the safety and efficacy of sura-vec, which has shown promising results in previous studies.
Read more →REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
REGENXBIO has successfully completed dosing in the confirmatory study of RGX-202, a gene therapy for Duchenne muscular dystrophy, ahead of schedule. This positions the company to submit a Biologics License Application (BLA) in Q3 2026, aiming for FDA approval by late 2027. The study demonstrated strong efficacy and safety, aligning with accelerated approval criteria.
Read more →REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
REGENXBIO has aligned with the FDA on the next steps for the accelerated approval of NAVSUNLI, a gene therapy for MPS II. The FDA confirmed that no additional studies are needed and will review existing data on an expedited basis. The company plans to resubmit the Biologics License Application in Q3 2026 after a Type A meeting with the FDA.
Read more →REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. reported positive topline results from its pivotal Phase III AFFINITY DUCHENNE study of RGX-202, achieving its primary endpoint with high statistical significance. The results demonstrated a significant correlation between microdystrophin expression and functional improvement in patients. Additionally, the clinical hold on RGX-121 has been lifted, indicating progress in developing treatments for Hunter syndrome. Financial results showed a substantial net loss for the first quarter of 2026, reflecting challenges in revenue generation amidst ongoing operational efforts.
Read more →REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
REGENXBIO has announced positive topline results from the Phase III AFFINITY DUCHENNE trial for RGX-202, showing that 93% of participants achieved significant microdystrophin expression. The data also indicate a strong correlation between this expression and functional improvement over a year. The therapy is reported to have a favorable safety profile, with no serious long-term adverse effects documented. As a result of these findings, REGENXBIO is preparing for potential accelerated approval in 2027.
Read more →REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
REGENXBIO Inc. announced its participation in the 2026 American Society of Gene & Cell Therapy Annual Meeting, featuring oral and poster presentations. Key topics include advancements in gene therapy production and pivotal data from RGX-202 for Duchenne muscular dystrophy. The event emphasizes the company's leadership in gene therapy innovation.
Read more →